cognitive cybersecurity intelligence

News and Analysis

Search

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB, a biopharmaceutical company, will present results from Phase 3 studies investigating the impact of bimekizumab on pain and health-related quality of life in moderate-to-severe hidradenitis suppurativa at the Symposium on Hidradenitis Suppurativa Advances. The data provide further evidence of bimekizumab’s potential to treat this chronic inflammatory condition. Despite promising results, the drug has not yet been approved by the US Food and Drug Administration.

Source: www.prnewswire.com –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts

Connecting Tech to Black America

Tech evangelist David Lee spotlights the underrepresentation of Black Americans in tech, an issue he contends requires collective action to rectify. He suggests fostering connections

Zero-Day Attack Hits Cybersecurity Leader

The MITRE Corporation, a contributor to public interest cybersecurity, disclosed a data breach originating from a state-backed hack. Detected after suspicous activity was noticed on

Defining and Understanding Trust Assurance

Trust is essential for businesses and building it requires embracing the pillars of trust assurance: predictive, integrated, and transparent systems. Through trust assurance, businesses can